Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
NCT ID: NCT05135286
Last Updated: 2025-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
629 participants
INTERVENTIONAL
2022-03-15
2025-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
NCT05270863
Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
NCT04774237
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
NCT06948357
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
NCT05665387
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
NCT06542497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BRIMOCHOL™ PF
A single drop in each eye at a visit.
BRIMOCHOL™ PF
A single drop in each eye at a visit.
Carbachol PF
A single drop in each eye at a visit.
Carbachol PF
A single drop in each eye at a visit.
Vehicle
A single drop in each eye at a visit.
Vehicle
A single drop in each eye at a visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BRIMOCHOL™ PF
A single drop in each eye at a visit.
Carbachol PF
A single drop in each eye at a visit.
Vehicle
A single drop in each eye at a visit.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have presbyopia
Exclusion Criteria
* Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results
45 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Visus Therapeutics
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Visus Therapeutics Investigative Site
Chandler, Arizona, United States
Visus Therapeutics Investigative Site
Phoenix, Arizona, United States
Visus Therapeutics Investigative Site
Sun City, Arizona, United States
Visus Therapeutics Investigative Site
Glendale, California, United States
Visus Therapeutics Investigative Site
Inglewood, California, United States
Visus Therapeutics Investigative Site
Irvine, California, United States
Visus Therapeutics Investigative Site
Mission Hills, California, United States
Visus Therapeutics Investigative Site
Newport Beach, California, United States
Visus Therapeutics Investigative Site
Pasadena, California, United States
Visus Therapeutics Investigative Site
Santa Barbara, California, United States
Visus Therapeutics Investigative Site
Littleton, Colorado, United States
Visus Therapeutics Investigative Site
Danbury, Connecticut, United States
Visus Therapeutics Investigative Site
Crystal River, Florida, United States
Visus Therapeutics Investigative Site
Delray Beach, Florida, United States
Visus Therapeutics Investigative Site
Fort Lauderdale, Florida, United States
Visus Therapeutics Investigative Site
Jacksonville, Florida, United States
Visus Therapeutics Investigative Site
Largo, Florida, United States
Visus Therapeutics Investigative Site
Mt. Dora, Florida, United States
Visus Therapeutics Investigative Site
Lake Villa, Illinois, United States
Visus Therapeutics Investigative Site
Indianapolis, Indiana, United States
Visus Therapeutics Investigative Site
Louisville, Kentucky, United States
Visus Therapeutics Investigative Site
Bloomington, Minnesota, United States
Visus Therapeutics Investigative Site
Kansas City, Missouri, United States
Visus Therapeutics Investigative Site
St Louis, Missouri, United States
Visus Therapeutics Investigative Site
Henderson, Nevada, United States
Visus Therapeutics Investigative Site
Poughkeepsie, New York, United States
Visus Therapeutics Investigative Site
Garner, North Carolina, United States
Visus Therapeutics Investigative Site
West Fargo, North Dakota, United States
Visus Therapeutics Investigative Site
Powell, Ohio, United States
Visus Therapeutics Investigative Site
Portland, Oregon, United States
Visus Therapeutics Investigative Site
Cranberry Township, Pennsylvania, United States
Visus Therapeutics Investigative Site
Wilkes-Barre, Pennsylvania, United States
Visus Therapeutics Investigative Site
Sioux Falls, South Dakota, United States
Visus Therapeutics Investigative Site
Maryville, Tennessee, United States
Visus Therapeutics Investigative Site
Memphis, Tennessee, United States
Visus Therapeutics Investigative Site
Smyrna, Tennessee, United States
Visus Therapeutics Investigative Site
Hurst, Texas, United States
Visus Therapeutics Investigative Site
Lakeway, Texas, United States
Visus Therapeutics Investigative Site
San Antonio, Texas, United States
Visus Therapeutics Investigative Site
Draper, Utah, United States
Visus Therapeutics Investigative Site
Falls Church, Virginia, United States
Visus Therapeutics Investigative Site
Lynchburg, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VT-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.